{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T16:08:29Z","timestamp":1716566909419},"reference-count":0,"publisher":"Termedia Sp. z.o.o.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arch Med Sci"],"published-print":{"date-parts":[[2021,7,16]]},"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>We aimed to investigate the efficacy and side effects of bendamustine in relapsed\/refractory\u00a0lymphoma patients in Turkey.\u00a0<\/jats:p><\/jats:sec><jats:sec><jats:title>Material and methods<\/jats:title><jats:p>In this retrospective study, we included relapsed\/refractory Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) patients who underwent multiple lines of chemotherapy. The primary endpoint was to determine the objective response and toxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Ninety-nine patients with a\u00a0median age of 59.8 years were included in the study. Eighty-one patients had NHL (follicular lymphoma: 10, diffuse large B-cell lymphoma: 27, mantle-cell lymphoma: 18, marginal zone lymphoma: 9, small lymphocytic lymphoma\/chronic lymphocytic leukemia: 17) and 18 patients had HL. The patients had previously received a\u00a0median of three lines of chemotherapy (range: 2\u20138) except autologous stem cell transplantation (ASCT); 19 patients (HL: 11, NHL: 8) had undergone ASCT. The objective response rate (ORR) was 74.3%, the complete response rate was 57% (= 53), and the partial response rate was 16.6% ( = 19). The overall survival (OS) rate at 1 year was 74.6%. The progression-free survival (PFS) rate at 1 year was 62.5%. The most common side effects were lymphopenia, anemia and neutropenia. Side effects which were observed as grade 3 and higher levels were lymphopenia (14.1%), neutropenia (10.1%) and fatigue (7.1%).\u00a0<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Objective response rate of bendamustine was found to be 74.3% in relapsed\/refractory HL and NHL patients. It appears to be an effective option as a\u00a0salvage treatment for patients who have previously received multiple lines of therapy.<\/jats:p><\/jats:sec>","DOI":"10.5114\/aoms.2019.83000","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T15:15:54Z","timestamp":1551280554000},"page":"920-927","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of bendamustine in relapsed or refractory lymphoma cases: a Turkish Oncology Group study"],"prefix":"10.5114","volume":"17","author":[{"given":"Nuri","family":"Karadurmus","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Health Sciences University, Gulhane Training \nand Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Semra","family":"Paydas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, \nTurkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ece","family":"Esin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Sciences University, Dr. Abdurrahman \nYurtaslan Training and Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeki Gokhan","family":"Surmeli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medicalpark Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birol","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Sciences University, Gulhane Training \nand Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ismail","family":"Erturk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Sciences University, Gulhane Training \nand Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erdinc","family":"Nayir","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Medicalpark Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mutlu","family":"Dogan","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Sciences University, Numune Training \nand Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Taner","family":"Sumbul","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Baskent University, Adana, \nTurkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibrahim","family":"Barista","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, \nTurkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emel","family":"Gurkan","sequence":"additional","affiliation":[{"name":"Department of Haematology, Faculty of Medicine, Cukurova University, Adana, \nTurkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramazan","family":"Ocal","sequence":"additional","affiliation":[{"name":"Department of Haematology, Faculty of Medicine, Gazi University, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burhan","family":"Ferhanoglu","sequence":"additional","affiliation":[{"name":"Department of Haematology, Faculty of Medicine, Koc University, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gokhan","family":"Ozgur","sequence":"additional","affiliation":[{"name":"Department of Haematology, Health Sciences University, Gulhane Training \nand Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuf","family":"Karakas","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, \nTurkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahin","family":"Lacin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, \nTurkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sukru","family":"Ozaydin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Health Sciences University, Gulhane Training \nand Research Hospital, Ankara, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Halil Ibrahim","family":"Petekkaya","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Special Tinaztepe Hospital, Izmir, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Necdet","family":"Uskent","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Anatolian Health Center, Istanbul, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2021,7,16]]},"container-title":["Archives of Medical Science"],"original-title":[],"link":[{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-94039-66440","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.archivesofmedicalscience.com\/pdf-94039-66440","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T13:18:49Z","timestamp":1626441529000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.archivesofmedicalscience.com\/Effectiveness-of-bendamustine-in-relapsed-or-refractory-lymphoma-cases-a-Turkish,94039,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,16]]},"references-count":0,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"alternative-id":["94039"],"URL":"https:\/\/doi.org\/10.5114\/aoms.2019.83000","relation":{},"ISSN":["1734-1922","1896-9151"],"issn-type":[{"value":"1734-1922","type":"print"},{"value":"1896-9151","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,16]]}}}